Why Farbe Firma is the Top Manufacturer of Zuclopenthixol Decanoate Injection
- Maulik Sudani
- 1 day ago
- 8 min read
Last Updated: June 17, 2026
TL;DR: Zuclopenthixol Decanoate Injection — a sterile, clear, yellowish oily solution of zuclopenthixol decanoate, the decanoate ester of the cis(Z)-isomer thioxanthene antipsychotic zuclopenthixol, dissolved in a thin vegetable oil vehicle and supplied commonly as a 200 mg/mL ampoule for deep intramuscular depot injection every two to four weeks — is a cornerstone maintenance agent for schizophrenia and other chronic psychoses where reliable, long-acting therapy supports adherence. Because the product is a non-aqueous oily depot dosed at long intervals into the same patient for years, each ampoule must deliver an exact, sterile, particulate-free dose of the correct geometric isomer at a tightly controlled concentration, with the assay, the cis(Z)-isomer ratio, the related-substance and degradation profile, the oil-vehicle quality, fill volume, viscosity, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Zuclopenthixol Decanoate Injection at our Gujarat, India facility and supplies it to psychiatric hospital pharmacy, community mental-health and depot-clinic services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Thioxanthene long-acting depot antipsychotic (decanoate ester of the cis(Z)-isomer zuclopenthixol) — Zuclopenthixol Decanoate Injection is given by deep intramuscular depot injection, usually every two to four weeks, for maintenance treatment of schizophrenia and other chronic psychoses, supporting adherence through sustained, slow release from an oily depot.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, dedicated non-aqueous oily-solution compounding and amber-glass ampoule filling lines, control of the stability-indicating assay, the cis(Z)-isomer ratio, the related-substance and degradation profile, injectable-grade oil-vehicle quality (peroxide and acid value), fill volume, viscosity, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile oily-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Zuclopenthixol Decanoate Injection Demands a Premium Manufacturer
Zuclopenthixol Decanoate Injection holds a quietly essential place in psychiatric care across every market. It is the long-acting depot thioxanthene that clinicians turn to for the maintenance treatment of schizophrenia and other chronic psychotic illnesses, where the single greatest determinant of outcome is often whether the patient keeps taking medication at all. By dissolving the decanoate ester of zuclopenthixol in an oily vehicle and injecting it deep into muscle, a depot formulation releases active drug slowly over two to four weeks, replacing daily tablets with a single supervised injection at the depot clinic and so removing the daily-adherence burden that drives so many relapses. In this setting the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because steady symptom control over weeks depends on a precise, reproducible depot dose released at a predictable rate.
That clinical reality places real demands on the manufacturer. Zuclopenthixol decanoate is not an aqueous product at all — it is a non-aqueous oily solution, so the manufacturer must source an injectable-grade thin vegetable oil with controlled peroxide and acid values, compound and fill a viscous oil rather than water, and sterilise a product in which water-based assumptions do not apply. The active itself is a single geometric isomer — the cis(Z)-form — so control of the isomer ratio is a defining quality attribute, alongside an exact assay of zuclopenthixol decanoate and tight limits on related substances and degradation products. Because the depot sits in muscle and releases for weeks, the fill volume and concentration must be exact so the labelled dose is delivered; the oil must be clear and free of visible and sub-visible particulates and low in endotoxin; the viscosity must allow deep intramuscular injection through a suitable needle; and the product must be protected in amber glass against light. Choosing a Zuclopenthixol Decanoate Injection manufacturer that treats oil-vehicle quality, the cis(Z)-isomer ratio, the stability-indicating assay, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Zuclopenthixol Decanoate Injection Manufacturer Apart
A world-class manufacturer of Zuclopenthixol Decanoate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of zuclopenthixol decanoate with the cis(Z)-isomer ratio, related-substance and degradation control by HPLC that a depot thioxanthene ester demands, a robust, validated non-aqueous oily-solution sterilisation and fill process that protects sterility, clarity and viscosity in a vegetable-oil vehicle, and tender-ready dossier support for a chronic-care psychiatric product procured through hospital-pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade zuclopenthixol decanoate of verified cis(Z)-isomer purity sourced from qualified, audited API makers, with full assay, isomer-ratio, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the isomer purity and the integrity of an oily depot. The active is dissolved in an injectable-grade thin vegetable oil of controlled peroxide and acid value to the labelled concentration, with the oil handled under inert-gas protection to limit oxidation, the bulk clarified and filtered, and the product filled into amber-glass ampoules under ISO Class 5 conditions, with the validated sterilisation route appropriate to a non-aqueous oil — dry-heat or moist-heat terminal sterilisation where the formulation and container qualify, otherwise sterile filtration of the oil and aseptic filling — locked in the master batch record. Filled ampoules are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of zuclopenthixol decanoate by validated HPLC, the cis(Z)-isomer ratio, the related-substance and degradation profile, the clarity and colour of the oil, deliverable volume, viscosity, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the depot is safe for intramuscular administration. Because the vehicle is an oxidisable oil and the active is a defined isomer, the oil-vehicle quality, inert-gas handling and isomer ratio are validated together so assay, isomer purity and clarity stay within specification across shelf life.
Quality Systems Behind Every Zuclopenthixol Decanoate Injection
Every Farbe Firma Zuclopenthixol Decanoate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of zuclopenthixol decanoate against pharmacopoeial reference standards, verification of the cis(Z)-isomer ratio, control of related substances and degradation products by HPLC, clarity and colour of the oily solution, oil-vehicle peroxide and acid value, deliverable (fill) volume, viscosity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the amber-glass ampoule format. Certificates of analysis are issued with full traceability back to each API lot, the oil-vehicle lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection and clean-utility generation, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated oily-solution filling lines with inert-gas protection and 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because zuclopenthixol decanoate is a defined-isomer ester carried in an oxidisable oil and the assay, isomer ratio, clarity and particulate burden of the depot drive both efficacy and safety, we treat the stability-indicating HPLC assay, the cis(Z)-isomer ratio, the oil-vehicle quality, viscosity and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge that demonstrates the protection given by the amber glass and inert-gas handling.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Zuclopenthixol Decanoate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a focused central-nervous-system and depot-antipsychotic portfolio alongside our broader small-volume parenteral range. For Zuclopenthixol Decanoate Injection specifically, we supply the 200 mg/mL oily-solution ampoule in amber glass under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, isomer-ratio, oil-vehicle, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Zuclopenthixol Decanoate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the oily-solution compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing and cis(Z)-isomer control, stability-indicating assay development, related-substance and degradation control, injectable-grade oil-vehicle selection and peroxide/acid-value management, the choice between terminal sterilisation and aseptic filling for a non-aqueous depot, viscosity and deep-intramuscular injectability, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a long-acting depot antipsychotic where isomer purity, assay accuracy, oil-vehicle quality and particulate control directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Zuclopenthixol Decanoate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Zuclopenthixol Decanoate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated non-aqueous oily-solution compounding and amber-glass ampoule filling lines, validated sterilisation, qualified clean utilities, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Zuclopenthixol Decanoate Injection do you supply?
Our standard presentation is the 200 mg/mL oily-solution ampoule of zuclopenthixol decanoate in amber glass, for deep intramuscular depot injection. Custom strengths, fill configurations, ampoule formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Zuclopenthixol Decanoate Injection mainly used for?
Zuclopenthixol Decanoate Injection is used for the maintenance treatment of schizophrenia and other chronic psychoses. It is a thioxanthene long-acting depot antipsychotic given by deep intramuscular injection every two to four weeks; Farbe Firma verifies the assay, the cis(Z)-isomer ratio, clarity, deliverable volume, viscosity and particulate matter at release so each ampoule delivers a precise, reproducible depot dose.
Can Farbe Firma support country-specific registrations for Zuclopenthixol Decanoate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Zuclopenthixol Decanoate Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, label complexity and dossier requirements. For our oily-solution depot presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments